DEFA14A: ISS Recommends Acelyrin Stockholders Vote for Proposed Merger with Alumis

Leading proxy advisory firm ISS recommends Acelyrin stockholders vote in favor of the proposed merger with Alumis, citing potential upside and uncertainties surrounding alternatives.

Summary

• Acelyrin is urging its stockholders to vote in favor of the proposed merger with Alumis.
• ISS has recommended that Acelyrin stockholders vote FOR the proposed merger.
• The company believes the merger is the most certain path forward to maximize value for stockholders.
• The transaction resulted from a comprehensive and competitive process led by a committee of independent directors.
• ISS acknowledges concerns about the offer value and potential conflicts of interest but notes uncertainties about alternatives.
• ISS also notes the offer represents a premium to the unaffected price, and the strategic rationale appears logical.
• ISS highlights uncertainties associated with liquidation, including potential for lower asset sales and lengthy delays.
• The macroeconomic environment for biotech companies has changed significantly since previous unsolicited offers.
• Guggenheim Securities is serving as financial advisor, and Fenwick & West LLP and Paul Hastings LLP are serving as legal counsel.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the ISS recommendation and management's confidence in the merger's benefits, but tempered by concerns about offer value and market uncertainties.

Positives

• ISS support for the merger provides validation.
• The merger offers a potential premium to the unaffected price.
• The combined company is expected to be stronger and more diversified.
• The merger is the result of a comprehensive and competitive process.
• ISS recognizes the strategic rationale for the merger.

Negatives

• ISS has concerns about the offer value.
• ISS has concerns about potential conflicts of interest.
• There are uncertainties about the availability and upside of potential alternatives.
• The macroeconomic environment for biotech companies has changed significantly since previous unsolicited offers.

Risks

• The Proposed Transaction may not be completed in a timely basis or at all, which may adversely affect Alumis and ACELYRINs businesses and the price of their respective securities.
• The potential failure to receive, on a timely basis or otherwise, the required approvals of the Proposed Transaction, including stockholder approvals by both Alumis stockholders and ACELYRINs stockholders, and the potential failure to satisfy the other conditions to the consummation of the transaction.
• The effect of the announcement, pendency or completion of the Proposed Transaction on each of Alumis or ACELYRINs ability to attract, motivate, retain and hire key personnel and maintain relationships with partners, suppliers and others with whom Alumis or ACELYRIN does business, or on Alumis or ACELYRINs operating results and business generally.
• The Proposed Transaction may divert managements attention from each of Alumis and ACELYRINs ongoing business operations.
• There is a risk of any legal proceedings related to the Proposed Transaction or otherwise, or the impact of the Proposed Transaction thereupon, including resulting expense or delay.
• Alumis or ACELYRIN may be adversely affected by other economic, business and/or competitive factors.
• The occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, including in circumstances which would require Alumis or ACELYRIN to pay a termination fee.
• Restrictions during the pendency of the Proposed Transaction may impact Alumis or ACELYRINs ability to pursue certain business opportunities or strategic transactions.
• The anticipated benefits and synergies of the Proposed Transaction may not be fully realized or may take longer to realize than expected.
• Legislative, regulatory, economic, competitive and technological changes could have an impact.
• There are risks relating to the value of Alumis securities to be issued in the Proposed Transaction.
• Integration of the Proposed Transaction post-closing may not occur as anticipated or the combined company may not be able to achieve the growth prospects expected from the transaction.
• The effect of the announcement, pendency or completion of the Proposed Transaction on the market price of the common stock of each of Alumis and ACELYRIN.
• The implementation of each of Alumis and ACELYRINs business model and strategic plans for product candidates and pipeline, and challenges inherent in developing, commercializing, manufacturing, launching, marketing and selling potential existing and new products and product candidates.
• The scope, progress, results and costs of developing Alumis and ACELYRINs product candidates and any future product candidates, including conducting preclinical studies and clinical trials, and otherwise related to the research and development of Alumis and ACELYRINs pipeline.
• The timing and costs involved in obtaining and maintaining regulatory approval for Alumis and ACELYRINs current or future product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product.
• The market for, adoption (including rate and degree of market acceptance) and pricing and reimbursement of Alumis and ACELYRINs product candidates, if approved, and their respective abilities to compete with therapies and procedures that are rapidly growing and evolving.
• Uncertainties in contractual relationships, including collaborations, partnerships, licensing or other arrangements and the performance of third-party suppliers and manufacturers.
• The ability of each of Alumis and ACELYRIN to establish and maintain intellectual property protection for products or avoid or defend claims of infringement.
• Alumis ability to successfully integrate ACELYRINs operations and personnel.
• Potential delays in initiating, enrolling or completing preclinical studies and clinical trials.

Future Outlook

The document expresses confidence that the merger provides stockholders with significant potential upside as part of a stronger, more diversified combined company that is best positioned to maximize the potential of lonigutamab.

Management Comments

• We are pleased ISS recognizes that the merger with Alumis is the most certain path forward to maximize value for our stockholders.
• The ACELYRIN Board and management team are confident that the merger provides stockholders with significant potential upside as part of a stronger, more diversified combined company that is best positioned to maximize the potential of lonigutamab.

Industry Context

The announcement comes amid a changing macroeconomic environment for biotech companies, highlighting the importance of strategic transactions to maximize value and navigate market uncertainties.

Stakeholder Impact

• Stockholders are expected to benefit from the potential upside of the merger.
• Employees may experience changes as the companies integrate.
• Partners and suppliers may be affected by the combined company's strategies.

Next Steps

• Acelyrin stockholders will vote on the proposed merger on May 13, 2025.
• The companies will work to satisfy the remaining closing conditions for the merger.

Key Dates

Keywords

merger, Acelyrin, Alumis, ISS, stockholders, transaction, proxy, lonigutamab, biopharma, immunology